• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Immatics N.V.

    6/6/24 8:37:26 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMTX alert in real time by email
    SC 13D 1 d839323dsc13d.htm SC 13D SC 13D

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment ___)*

     

     

    Immatics N.V.

    (Name of Issuer)

    Ordinary Shares, nominal value €0.01 per share

    (Title of Class of Securities)

    N44445109

    (CUSIP Number)

    Alexander Rakitin

    Perceptive Advisors LLC

    51 Astor Place, 10th Floor

    New York, NY 10003

    (646) 205-5340

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    May 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. N44445109

     

     1.    

     Names of Reporting Persons.

     

     Perceptive Advisors LLC

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     8,170,846

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     8,170,846

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     8,170,846

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     7.9%

    14.  

     Type of Reporting Person (See Instructions)

     

     OO


    CUSIP No. N44445109

     

     1.    

     Names of Reporting Persons.

     

     Perceptive Life Sciences Master Fund, Ltd.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     WC

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     8,086,159

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     8,086,159

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     8,086,159

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     7.9%

    14.  

     Type of Reporting Person (See Instructions)

     

     CO


    CUSIP No. N44445109

     

     1.    

     Names of Reporting Persons.

     

     Joseph Edelman

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States of America

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     8,170,846

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     8,170,846

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     8,170,846

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     7.9%

    14.  

     Type of Reporting Person (See Instructions)

     

     IN


    CUSIP No. N44445109

     

    Item 1.

    Security and Issuer

    This Schedule 13D relates to the Ordinary Shares, nominal value €0.01 per share (the “Ordinary Shares”) of Immatics N.V. (the “Issuer”), which has its principal executive offices at Paul-Ehrlich-Straße 15, 72076 Tübingen, Germany.

     

    Item 2.

    Identity and Background

     

      (a)

    This Schedule 13D is being filed by Perceptive Advisors LLC (“Perceptive Advisors” or “Perceptive”), Joseph Edelman (“Mr. Edelman”) and Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”, and together with Perceptive Advisors and Mr. Edelman, each of the foregoing, a “Reporting Person,” and collectively, the “Reporting Persons”). Perceptive Advisors serves as the investment advisor to the Master Fund and Mr. Edelman is the managing member of Perceptive Advisors. The agreement among the Reporting Persons to file this Schedule 13D jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, is attached hereto as Exhibit 1.

     

      (b)

    The address of the principal business office of each of the Reporting Persons is 51 Astor Place 10th Floor, New York, NY 10003.

     

      (c)

    The principal business of Perceptive Advisors is managing funds in connection with purchasing, holding and selling securities for investment purposes. The principal business of the Master Fund is to invest in securities. The principal occupation of Mr. Edelman is as the managing member of Perceptive Advisors and other related entities.

     

      (d)

    During the last five years, none of the Reporting Persons, nor to the Reporting Persons’ knowledge, any of the persons listed on Schedule A to this Schedule 13D, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

      (e)

    During the last five years, none of the Reporting Persons, nor to the Reporting Persons’ knowledge, any of the persons listed on Schedule A to this Schedule 13D, has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree of final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

      (f)

    Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.

    Schedule A to this Schedule 13D sets forth the information regarding the directors of the Master Fund.

     

    Item 3.

    Source and Amount of Funds or Other Consideration

    The source of funds for the acquisitions of the Ordinary Shares reported on this Schedule 13D was working capital of the Master Fund and as a result of the Master Fund’s equity interest in ARYA (as defined below) in connection with the Distribution (as defined below).

     

    Item 4.

    Purpose of Transaction

    The Reporting Persons acquired the Ordinary Shares set forth in this Schedule 13D and hold their Ordinary Shares for investment purposes. Adam Stone, Chief Investment Officer of Perceptive, currently serves as a member of the Issuer’s Board of Directors pursuant to the Investor Rights Agreement (as defined below).

    Each Reporting Person expects to continuously review such person’s investment in the Issuer and, depending on various factors including but not limited to, the price of the Ordinary Shares, the terms and conditions of the transaction, prevailing market conditions and such other considerations as such Reporting Person deems relevant, may at any time or from time to time, and subject to any required regulatory approvals, acquire additional Ordinary Shares, preferred stock or other securities convertible into or exercisable or exchangeable for Ordinary Shares from time to time on the open market, in privately- negotiated transactions, directly from the Issuer, or upon the exercise or conversion of securities convertible into or exercisable or exchangeable for Ordinary Shares.


    Each Reporting Person also may, at any time, subject to compliance with applicable securities laws and regulatory requirements dispose of or distribute some or all of its Ordinary Shares or such other securities as it owns or may subsequently acquire depending on various factors, including but not limited to, the price of the shares, the terms and conditions of the transaction and prevailing market conditions, as well as the liquidity and diversification objectives.

    Consistent with their investment intent, each Reporting Person may from time to time discuss with the Issuer’s management, directors, other shareholders and others, the Issuer’s performance, business, strategic direction, capital structure, product development program, prospects and management, as well as various ways of maximizing stockholder value, which may or may not include extraordinary transactions.

    Except as indicated herein, no Reporting Person, as a stockholder of the Issuer, has any plans or proposals that relates or would result in any of the transactions or other matters specified in clauses (a) though (j) of Item 4 of Schedule 13D. Each Reporting Person may, at any time and from time to time, review or reconsider its or his position and/or change its or his purpose and/or formulate plans or proposals with respect thereto.

    The information set forth in Item 6 below is incorporated by reference to this Item 4.

     

    Item 5.

    Interest in Securities of the Issuer

     

      (a)

    The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 102,985,072 Ordinary Shares outstanding as of January 31, 2024, as reported by the Issuer in its Form 20-F filed with the Securities and Exchange Commission on March 21, 2024, and in the case of the cover pages for Perceptive and Mr. Edelman give effect to the exercise of the Options (as defined below)

     

      (b)

    The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference. The shares reported include (i) 8,086,159 Ordinary Shares held by the Master Fund, and (ii) 84,687 Ordinary Shares issuable upon the exercise of 84,687 vested stock options or stock options that will vest within 60 days (the “Options”) that Perceptive has rights to pursuant to a management fee offset.

     

      (c)

    On May 30, 2024, the Master Fund acquired 3,503,750 Ordinary Shares in a pro rata distribution from ARYA at a valuation of $11.28 per share (the “Distribution”).

     

      (d)

    No person other than the Reporting Persons disclosed in this Schedule 13D is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Ordinary Shares subject to this Schedule 13D.

     

      (e)

    Not applicable.

     

    Item 6.

    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

    The information set forth in Item 4 above is incorporated by reference to this Item 6.

    Investor Rights Agreement

    On July 1, 2020, Arya Sciences Holdings (the “ARYA”) entered into an Investor Rights and Lock-Up Agreement (the “Investor Rights Agreement”) with the Issuer and certain other stockholders of the Issuer. Pursuant to the terms of the Investor Rights Agreement, ARYA and the Master Fund assumed certain rights as described below.

    Pursuant to the Investor Rights Agreements, until the fifth anniversary of the closing of the ARYA Merger (as defined therein), at each annual or special meeting of the Issuer’s shareholders, (i) the Master Fund and certain other investors named therein (collectively, the “ARYA Investors”) have the right, but not the obligation, to designate for election as a director two individuals to serve on the Issuer’s Board (one Class I director and one Class III director), provided that the ARYA Investors’ nomination rights will terminate if at any time ARYA Investors collectively own less than 5% of the Issuer’s then-outstanding Ordinary Shares. Once nominated, the Issuer’s Board is obligated to recommend such individuals for election and to include such recommendation in any proxy statement or similar document provided to the Issuer’s shareholders.


    Pursuant to the Investor Rights Agreement, the Issuer agreed to file, subject to customary exceptions, a Registration Statement covering all Ordinary Shares issued in connection with the ARYA Merger, including the private placement of Ordinary Shares. The Registration Statement was declared effective on August 13, 2020. The Investor Rights Agreement also provides the parties with demand and “piggy-back” registration rights, subject to certain minimum requirements and customary conditions.

    The foregoing description of Investor Rights Agreement is not complete and is qualified in its entirety by reference to the full text of the Investor Rights Agreement, which is included as Exhibit 2 to this Schedule 13D and is incorporated herein by reference.

     

    Item 7.

    Material to be Filed as Exhibits

     

      Exhibit 1

    Joint Filing Agreement.

     

      Exhibit 2

    Investor Rights and Lock-Up Agreement, dated July 1, 2020, by and among the Issuer, Arya Sciences Holdings, and certain other investors of the Issuer named therein (incorporated by reference to Exhibit 10.1 to the Issuer’s Form F-1 filed on July 31, 2020 (File No. 333-240260)).


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: June 6, 2024

     

    PERCEPTIVE ADVISORS LLC
    By:  

    /s/ Joseph Edelman

      Name: Joseph Edelman
    Title:   Managing Member

    /s/ Joseph Edelman

    JOSEPH EDELMAN
    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
    By:  

    /s/ Joseph Edelman

      Name: Joseph Edelman
    Title:   Managing Member


    Schedule A

    The following sets forth the name, address, principal occupation, citizenship and beneficial ownership of Ordinary Shares (to the extent not pursuant to Item 5(a)) of each director of the Master Fund (to the extent not set forth in Item 2).

     

    Master Fund

    Name and Citizenship

      

    Position

      

    Principal Business Address

      

    Beneficial Ownership of

    Ordinary Shares

    Scott Dakers

    (United Kingdom)

       Director   

    c/o Elian Fiduciary Services (Cayman) Limited

    190 Elgin Avenue, George Town

    Grand Cayman KY1-9007

    Cayman Islands

       None

    Ernest A. Morrison

    (United Kingdom)

       Director   

    Cox Hallett Wilkinson

    Milner House

    18 Parliament Street

    P.O. Box HM 1561

    Hamilton HM FX

    Bermuda

       None

    James Nicholas

    (United States)

       Director   

    c/o GenesisPoint LLC

    30 Old Kings Highway S

    Darien, CT 06820

       None
    Get the next $IMTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMTX

    DatePrice TargetRatingAnalyst
    10/7/2024$19.00Overweight
    Piper Sandler
    11/2/2023Overweight
    Cantor Fitzgerald
    3/31/2023$12.00Buy
    Mizuho
    3/24/2023$16.00Buy
    Bryan Garnier
    7/15/2021$26.00 → $27.00Outperform
    SVB Leerink
    More analyst ratings

    $IMTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

      Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 30 – June 3, 2025, in Chicago, Illinois. Updated data from the Phase 1b trial of IMA203 in patients with metastatic melanoma with substantially longer follow-up compared to the last presentation in October 2024, and including data fro

      4/23/25 10:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immatics Announces Full Year 2024 Financial Results and Business Update

      Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as plannedACTengine® IMA203 TCR-T (PRAME): Phase 1b IMA203 data published in October 2024 demonstrated a confirmed ORR of 54%, 12.1 months mDOR, 6 months mPFS and OS not reached at a mFU time of 8.6 months in advanced melanoma patients; next data update on Phase 1b trial with extended follow-up planned in 2025 Second-generation ACTengine® IMA203CD8 TCR-T (PRAME): Phase 1a data published in November 2024 showed enhanced pharmacology and potency, demonstrating potential to address solid tumor indications with both high- and m

      3/27/25 7:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Clear Street Launches Healthcare & Biotechnology Equity Research

      Comprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises Clear Street, ("Clear Street", "the Company") a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, today announced the expansion of its recently launched equity research offering with the addition of Healthcare, initially focused on the biotechnology sector. The expanded research offering complements Clear Street's leading prime brokerage and clearing solutions for its rapidly growing client base of asset managers, institutions and professional traders across equities, fixed income, derivatives

      12/17/24 2:00:00 PM ET
      $CGEM
      $CRGX
      $DCTH
      $ELVN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations

    $IMTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Immatics Appoints Alise Reicin to Board of Directors

      Houston, Texas and Tuebingen, Germany, July 31, 2024 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company"))), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the appointment of Alise Reicin, M.D., to its Board of Directors. Alise Reicin is an experienced and expert pharmaceutical industry executive and leader who has led the development of multiple important new therapies, including Keytruda®. Dr. Reicin currently serves as the President and CEO of Tectonic Therapeutic and is also a member of the Board of Directors of Sana Biotechnology. She joins Immatics' Board of Directors as the Company

      7/31/24 7:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Memo Therapeutics AG appoints Paul Carter as Chairperson

      PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies                  Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a

      7/8/24 7:00:00 AM ET
      $IMTX
      $IRWD
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Levicept Appoints Eliot Forster as CEO

      Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

      11/30/23 4:00:00 AM ET
      $IMCR
      $IMTX
      $PLX
      $FSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $IMTX
    Financials

    Live finance-specific insights

    See more
    • Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

      Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metastatic melanoma patients with substantially enhanced maturity compared to the last data update in May 2024 and provides the first report on progression-free survival (PFS) and overall survival (OS)Based on the Phase 1b data, the Company will proceed directly to a registration-enabling Phase 3 trial Regulatory pathway and clinical trial design for IMA203 finalized following FDA Type D meetings and meeting with the Paul Ehrlich Institute (PEI); RP2D and CMC package confirmedIMA203 conti

      10/10/24 6:30:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

      Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET IMA203 data with focus on melanoma patients presented at the International Congress of the Society for Melanoma Research today, November 8 IMA203 GEN1 TCR cell therapy targeting PRAME – update on Phase 1a and Cohort A Continues to be well tolerated50% confirmed objective response rate (cORR) in melanoma patients treated at recommended Phase 2 dose; durability with some ongoing responses at >15 months and median duration of response not reached at a median follow-up of 14.4 monthsTargeted to enter registration-enabling Phase 2 trial in melanoma in 2024; discussions with FDA ongoing based on recently ob

      11/8/23 7:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME

      Company to host conference call today, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203 TCR-T monotherapy against PRAME Objective response rate (ORR): 64% (7/11) initial ORR at week 6 and 67% (6/9) confirmed ORR at month 3Median duration of response not reached at median follow-up time of 8.5 months at data cut-offObjective responses independent of solid tumor type at low, medium and high PRAME expression levels in checkpoint-refractory cutaneous melanoma, platinum-resistant ovarian cancer, uveal melanoma, head and neck cancer and synovial sarcomaCohort A IMA203 monotherapy TCR-T t

      5/2/23 7:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Immatics N.V.

      SC 13G - Immatics N.V. (0001809196) (Subject)

      11/14/24 1:28:33 PM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Immatics N.V.

      SC 13G - Immatics N.V. (0001809196) (Subject)

      11/14/24 6:32:45 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immatics N.V.

      SC 13G/A - Immatics N.V. (0001809196) (Subject)

      11/8/24 10:46:38 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on Immatics N.V. with a new price target

      Piper Sandler initiated coverage of Immatics N.V. with a rating of Overweight and set a new price target of $19.00

      10/7/24 7:57:11 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Immatics N.V.

      Cantor Fitzgerald initiated coverage of Immatics N.V. with a rating of Overweight

      11/2/23 7:08:49 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mizuho initiated coverage on Immatics N.V. with a new price target

      Mizuho initiated coverage of Immatics N.V. with a rating of Buy and set a new price target of $12.00

      3/31/23 7:22:50 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMTX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Immatics N.V.

      SCHEDULE 13G/A - Immatics N.V. (0001809196) (Subject)

      5/2/25 5:40:51 PM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Immatics N.V.

      EFFECT - Immatics N.V. (0001809196) (Filer)

      4/4/25 12:15:25 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form F-3 filed by Immatics N.V.

      F-3 - Immatics N.V. (0001809196) (Filer)

      3/27/25 8:01:41 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care